2nd Interdisciplinary Conference - Prostate Cancer: Predictive Models for Decision Making
Not eligible for ESCO credits
07.04.2011 - 09.04.2011
New York
CONFERENCE
Description
Chair: Peter T. Scardino, MD, US
Co-Chair: Riccardo Valdagni, MD, PhD, IT
Honorary Chair: Louis J. Denis, MD, BE
Scientific Coordinator: Karim Touijer, MD, US
TOPICS
Predictive models in prostate cancer with respect to:
- construction, accuracy and data management
- genomic and bio-molecular sciences
- histopathology and systems pathology
- risk of cancer on biopsy
- indolent and low risk tumor
- focal cancer
- pathologic stage and grade
- active surveillance
- surgery and related toxicity
- radiotherapy and related toxicity (external radiotherapy and brachytherapy)
- radiotherapy combined with hormonal therapy and related toxicity
- recurrent disease
- metastatic disease
- toxicity after androgen deprivation
- toxicity after chemotherapy
- clinical trial design and medical decision making
- future trends in the research
EDUCATIONAL OBJECTIVES
- To define the state of the art of predictive modeling in prostate cancer
- To evaluate the application of predictive models in daily clinical practice
- To determine the future research trends within the oncologic community
TARGET AUDIENCE
Urologists, radiation oncologists, medical physicists, medical oncologists, pathologists, biostatisticians and investigators in outcomes research and genomics.
A CME Conference jointly sponsored by |
%20di%202010MSKlogo.jpg) |
General information
OFFICE OF CME
Memorial Sloan-Kettering Cancer Center, New York (US)
Telephone: (646) 227-2025
Facsimile: (212) 557-0773
E-mail: brodheap@mskcc.org
Website: www.mskcc.org/cme
PROSTATE CANCER PROGRAMME
European School of Oncology
Milan (Italy)
Telephone: +39 02 85464527
Facsimile: +39 02 8546451
E-mail: prostate@eso.net
Website: www.eso.net
CONFERENCE LOCATION
Memorial Sloan-Kettering Cancer Center
Rockefeller Research Laboratories Auditorium
430 East 67th Street
Between First and York Avenues
New York, NY 10065 (USA)
EVALUATION
A course evaluation form will provide attendees with the opportunity to review the sessions and the speakers and to identify future educational needs.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Memorial Sloan-Kettering Cancer Center and the European School of Oncology. Memorial Sloan-Kettering Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.
European School of Oncology will apply for ACOE accreditation.
AMA CME CREDIT DESIGNATION STATEMENT
Memorial Sloan-Kettering Cancer Center designates this educational activity for a maximum of 18.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
COMMERCIAL SUPPORT
No commercial support has been provided for this CME activity. Memorial Sloan-Kettering Cancer Center (MSKCC) does not accept commercial support for its CME Program.
FACULTY DISCLOSURE
Memorial Sloan-Kettering Cancer Center (MSKCC) relies upon faculty participants in its CME Program to provide educational information that is objective and as free from bias as possible. In accordance with nationally accepted guidelines, faculty members are asked to indicate any commercial relationship that might be perceived as a real or apparent conflict of interest.
CERTIFICATES
All participants will be issued with an ESO–MSKCC certificate of attendance at the end of the Conference.
OFFICIAL LANGUAGE
The official language of the conference is English. No simultaneous translation will be provided.
BADGE
Your name badge is the only official evidence of registration and should be worn at all times during the Conference.
INSURANCE
The organizers bear no responsibility for untoward events in connection between with, before, during and after the conference. Participants are strongly advised to take their own personal and travel insurance coverage.
IMPORTANT DEADLINES
Early registration: before MARCH 25, 2011
Registration: MARCH 25 through APRIL 7, 2011
Cancellation deadline: MARCH 25, 2011
Replacement deadline: MARCH 25, 2011
Faculty list
PROVISIONAL FACULTY
Gerald L. Andriole, Div. Urology, Washington University School of Medicine in St. Louis, Barnes Jewish Hospital, St. Louis, US
Peter Bach, Div. Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, US
Chris Bangma, Head, Dept. Urology, Erasmus Medical Centre, Rotterdam, NL
Ethan Basch, Div. Medicine, Memorial Sloan Kettering Cancer Center, New York, US
Joaquim Bellmunt, Section Chief, Solid Tumor Oncology (GU & GI) Medical Oncology Service, Hospital del Mar, Barcelona, ES
Anders Bjartell, Professor in Clinical Urology, Dept. Urology, Malmö and Lund University Hospitals, Lund University, Malmö, SE
Peter R. Carroll, Director, Clinical Services and Strategic Planning, Helen Diller Family Comprehensive Cancer Center, University of California,
San Francisco, US
Carlos Cordon Cardo, Vice-Chair and Professor of Pathology, Columbia University, New York, US
Brett W. Cox, Brachytherapy Service, Memorial Sloan Kettering Cancer Center, New York, US
David Dearnaley, Professor of Uro-Oncology, Dept. Radiotherapy, Institute of Cancer Research, London, UK
Louis Denis, Director, Oncology Centre Antwerp (OCA), Antwerp, BE
James A. Eastham, Chief, Urology Service and Florence and Theodore Baumritter/Enid Ancell Chair, Urologic Oncology,
Memorial Sloan Kettering Cancer Center, New York, US
Mark Emberton, Divisional Clinical Director, Cancer Services, University College Hospitals, and Clinical Director, Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK
Jonathan I. Epstein, Professor, Departments of Pathology, Urology, & Oncology, The Reinhard Professor of Urologic Pathology, Johns Hopkins Medical Institutions, and Director, Surgical Pathology, Dept. Pathology, Johns Hopkins Hospital, Baltimore, US
Paul A. Fearn, NLM Informatics Research Fellow at University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, US
Roberto Gallina, Dept. Urology, Istituto Scientifico San Raffaele, Milan, IT
Christopher Foster, Professor of Cellular Pathology and Molecular Genetics, University of Liverpool, Liverpool, UK
Peter Hoskin, Professor and Honorary Consultant in Clinical Oncology, University College London, and Consultant in Clinical Oncology,
Mount Vernon Cancer Centre, Northwood, UK
Hedvig Hricak, Chair, Dept. Radiology, Memorial Sloan Kettering Cancer Center, New York, US
Maha Hussain, Associate Director for Clinical Research, Dept. Internal Medicine, University of Michigan Health System, Ann Arbor, US
Andrew Jackson, Dept. Medical Physics, Memorial Sloan Kettering Cancer Center, New York, US
Michael W. Kattan, Chair, Department Quantitative Health Sciences, Cleveland Clinic, Cleveland, US
Eric Klein, Chair, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, US
Laurence Klotz, Chief, Div. Urology, Sunnybrook Health Science Centre, Toronto, CA
Mark Litwin, Professor of Urology and Health Services, University of California, and Clark Urological Center, Ronald Reagan UCLA Medical Center, Los Angeles, US
Alvaro A. Martinez, Corporate Chairman, Radiation Oncology Dept., William Beaumont Hospitals, Royal Oak, US
Rodolfo Montironi, Institute of Pathological Anatomy and Histopathology, Marche Polytechnic University, United Hospitals, Le Torrette, IT
Francesco Montorsi, Head, Sexual Medicine Unit, Attending Urologist, Dept. Urology, Istituto Scientifico San Raffaele, Milan, IT
John P. Mulhall, Director, Male Sexual and Reproductive Medicine Program, Memorial Sloan Kettering Cancer Center, New York, US
Robert Nam, Clinical Epidemiology, Odette Cancer Research Program, Sunnybrook Health Science Centre, Toronto, CA
Simon Powell, Chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, US
Andrea Pusic, Div. Plastic Surgery, Memorial Sloan Kettering Cancer Center, New York, US
Farhang Rabbani, Associate Professor, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, US
Tiziana Rancati, Prostate Program, Scientific Director’s Office, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT
Victor E. Reuter, Vice Chair, Dept. Pathology and Director, Immunohistochemistry Core Facility, Memorial Sloan Kettering Cancer Center, New York, US
Mack Roach III, Professor, Depts. Radiation Oncology & Urology, Chairman, Dept. Radiation Oncology, UCSF Comprehensive Cancer Center,
San Francisco, US
Fred Saad, Professor and Chief of Urology, Centre Hospitalier de l’Université de Montréal, Montréal, CA
Martin G. Sanda, Director, Prostate Care Center, Div. Urology, Beth Israel Deaconess Medical Center, Boston, US
Jaspreet S. Sandhu, Dept. Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, US
Charles L. Sawyers, Chair, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, US
Peter T. Scardino, Chief, Dept. Surgery, Memorial Sloan Kettering Cancer Center, New York, US
Howard I. Scher, Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, US
Matthew R. Smith, Associate Professor, Dept. Medicine, Harvard Medical School, Assistant in Medicine, Hematology/Oncology,
Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center, Boston, US
Andrew Stephenson, Head, Urologic Oncology, Cleveland Clinic's Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, US
Cora N. Sternberg, Head, Dept. Medical Oncology, Ospedale San Camillo, Rome, IT
Steven Stone, V.P. of Cancer Genomics, Myriad Genetics Inc, Salt Lake City, US
Karim Touijer, Assistant Attending, Dept. Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, Assistant Professor of Urology,
Weill Medical College, Cornell University, New York, US
Riccardo Valdagni, Director, Prostate Program, Scientific Director’s Office, Director, Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT
Hein Van Poppel, Chair, Dept. Urology, University Hospital Gasthuisberg, Katholieke Universiteit, Leuven, BE
Andrew Vickers, Associate Attending Research Methodologist, Div. Health Outcomes, Dept. Epidemiology & Statistics, Memorial Sloan Kettering Cancer Center, New York, US
Anthony L. Zietman, Professor of Radiation Oncology, Dept. Radiation Oncology, Harvard Medical School, and Director, Radiation Oncology Residency Program, Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center, Boston, US
Programme
April 7th
8:00am | Opening and welcome |
8:05am | Making predictions throughout history |
| SESSION 1: PREDICTIVE MODELS FROM BENCH TO BEDSIDE AND BACK TO BENCH Chair: P.R. Carroll, US - R. Montironi, IT | |
8:20am | Data management for predictive tools |
8:35am | Construction of predictive tools and measurements of their accuracy |
8:50am | Imaging and outcomes prediction H. Hricak, US |
9:05am | From cancer biomarkers to therapeutic targets C. Foster, UK |
9:20am | Gene copy number analysis as a prognostic tool C.L. Sawyers, US |
| 9:50am | Coffee break |
| 10:10am | Traditional statistical methods for evaluating prediction models are uninformative: towards a decision analytic approach A. Vickers, US |
| 10:25am | Cell cycle progression genes differentiate indolent from aggressive prostate cancer S. Stone, US |
| 10:40am | Systems pathology and outcome predictive models C. Cordon Cardo, US |
10:55am | Principles of biomarkers from discovery to qualification H.I. Scher, US |
| PANEL DISCUSSION | |
11:25am | DO MOLECULAR MARKERS IMPROVE PREDICTIVE MODELS? Chair: P.R. Carroll, US - R. Montironi, IT Panelists: C. Cordon Cardo, US - P.A. Fearn, US -C. Foster, UK - M.W. Kattan, US C.L. Sawyers, US - H.I. Scher, US - S. Stone, US - A. Vickers, US |
12:05am | Lunch |
| SESSION 2: PREDICTING DIAGNOSIS AND STAGE Chair: A. Bjartel, SW - J.A. Eastham, US | |
1:10pm | Predicting risk of cancer on biopsy R. Nam, CA |
1:30pm | Upgrading/Downgrading of prostate cancer from biopsy to radical prostatectomy: Incidence and predictive factors V.E. Reuter, US |
1:50pm | Predicting grade J.I. Epstein, US |
| SESSION 3: PREDICTIVE MODELS IN LOW RISK PROSTATE CANCER” Chair: A. Bjartel, SE - M. Emberton, US | |
2:25pm | Predicting indolent and low risk prostate cancer C. Bangma, NL |
2:45pm | Predicting focal cancer M. Emberton, UK |
3:05pm | Active surveillance: PSA kinetics and biomarkes L. Klotz, CA |
| PANEL DISCUSSION | |
3:25pm | PREDICTIVE MODELS IN LOW RISK CANCER: LIMITATIONS AND FUTURE NEEDS Chair: C. Bangma, NL - P.T. Scardino, US Panelists: B.W. Cox, US - P.R. Carroll, US - M. Emberton, UK - L. Klotz, CA A. Vickers, US - A.L. Zietman, US |
| * Discussion will follow each lecture | |
April 8th
SESSION 4: MODELS TO PREDICT PROGNOSIS AFTER THERAPY IN LOCALIZED PROSTATE CANCER | |
8:00am | Predicting clinical and biochemical endpoints before surgery K. Touijer, US |
8:15am | Predicting clinical and biochemical endpoints after surgery A. Stephenson, US |
8:30am | Predicting clinical and biochemical endpoints before external radiotherapy B.W. Cox, US |
8:50am | Predicting clinical and biochemical endpoints before external radiotherapy combined with hormonal therapy D. Dearnaley, UK |
9:10am | Predicting clinical and biochemical endpoints before brachytherapy A.A. Martinez, US |
PANEL DISCUSSION | |
9:30am | WHAT ARE THE LIMITATIONS OF CURRENT PREDICTIVE MODELS |
10:00am | Coffee break |
| SESSION 5: MODELS TO PREDICT PROGNOSIS IN ADVANCED DISEASE Chair: J. Bellmunt, ES - H.I. Scher, US | |
10:15am | Predicting life expectancy A. Vickers, US |
10:40am | Predicting response to hormonal therapy and survival in men with metastatic disease M.H. Hussain, US |
11:05am | Role of Circulating Tumor Cells in predicting survival in men with castration resistant disease C.N. Sternberg, IT |
| PANEL DISCUSSION | |
11:30am | DO WE NEED BETTER PREDICTIVE MODELS IN ADVANCED PROSTATE CANCER? Chair: M.R. Smith, US - C.N. Sternberg, IT Panelists: J. Bellmunt, ES - J. Eastham, US - P. Hoskin, UK - M.H. Hussain, US M.W. Kattan, US - M. Roach III, US - H.I. Scher, US |
12:10am | Lunch |
| SESSION 6: QUALITY OF LIFE OUTCOME MEASUREMENT Chair: D. Dearnaley, UK - E. Klein, US | |
1:10pm | Documenting outcomes with patient reported questionnaires M. Litwin, US |
1:30pm | Measuring side effects with validated quality of life instruments M.G. Sanda, US |
1:50pm | Quality of life instruments and their role in cancer care A. Pusic, US |
| PANEL DISCUSSION | |
2:10pm | ADVANTAGES AND LIMITATIONS OF CURRENT QUALITY OF LIFE INSTRUMENTS Chairs: L. Klotz, CA - F. Montorsi, IT Panelists: E. Basch, US - P. Hoskin, UK - E. Klein, US - M. Litwin, US A. Pusic, US - M.G. Sanda, US - A. Vickers, US |
2:40pm | Coffee break |
| THREE BREAKOUT SESSIONS | |
| SESSION 7: MODELS TO PREDICT THERAPY INDUCED TOXICITIES | |
| UROLOGY ROOM Chair: J.A. Eastham, US - J.P. Mulhall, US | |
3:00pm | Should surgeon specific factors be incorporated in prediction modeling? A. Vickers, US |
3:25pm | Predicting toxicity after surgery: incontinence J.S. Sandhu, US |
3:50pm | Predicting toxicity after surgery: erectile dysfunction R. Gallina, IT |
4:15pm | Predicting toxicity after surgery: morbidity and complications F. Rabbani, US |
4:40pm | Surgery group discussion How to design the next generation of predictive models in Urology? |
5:00pm | End of the Session |
| RADIATION ONCOLOGY ROOM Chair: A. Jackson, US - A.L. Zietman, US | |
3:00pm | How the radiation oncologist and the radiation technique affect outcome P. Hoskin, UK |
3:20pm | Predicting toxicity after external radiotherapy: sexual and urinary dysfunction M. Roach III, US |
3:40pm | Predicting toxicity after external radiotherapy: gastro-intestinal dysfunction R. Valdagni, IT |
4:00pm | Predicting toxicity after brachytherapy A.A. Martinez, US |
4:20pm | Predicting radio-induced toxicity: the challenge of moving from qualitative events to quantitative scoring T. Rancati, IT |
4:40pm | Volume effects and dose responses in rectal complications of external beam radiotherapy J. Jackson, US |
5:00pm | Radiation Oncology group discussion How to design the next generation of predictive models in radiation oncology? |
5:20pm | End of the Session |
| MEDICAL ONCOLOGY ROOM Chair: M.H. Hussain, US - H.I. Scher, US | |
3:00pm | Predicting toxicity after androgen deprivation: cardiovascular events M.R. Smith, US |
3:25pm | Predicting toxicity after androgen deprivation: skeletal adverse events F. Saad, US |
3:50pm | Role of predictive biomarkers as a measure of individualized medicine M.H. Hussain, US |
4:15pm | Medical Oncology group discussion How to design the next generation of predictive models for advanced disease? |
5:00pm | End of the Session |
| * Discussion will follow each lecture | |
April 9th
HIGHLIGHTS OF THE BREAKOUT SESSIONS | |
8:30am | Urology room K. Toujier, US |
8:45am | Radiation Oncology room B.W. Cox, US |
9:00am | Medical Oncology room F. Saad, CA |
Summary | |
SESSION 8: POINT, COUNTERPOINT” | |
9:30am | DEBATE 1: "DO I NEED A NOMOGRAM TO MAKE GOOD DECISIONS?" |
10:20am | PANEL DISCUSSION Chair: E. Klein, US - H.I. Scher, US Panelists: C. Cordon Cardo, US - P. Hoskin, UK - R. Montironi, IT - V.E. Reuter, US S. Stone, US - A. Vickers, US |
| 10:30am | Coffee break |
10:50am | DEBATE 2: "CATEGORICAL STAGING VERSUS CONTINUOUS PREDICTION: HOW CAN WE INTEGRATE PREDICTIVE MODELS INTO THE STAGING SYSTEMS?" |
| 11:20am | PANEL DISCUSSION Chair: K. Touijer, US - H. Van Poppel, BE Panelists: P. Bach, US - P.R. Carroll, US - D. Dearnaley, UK, - M.W. Kattan, US F. Montorsi, IT - M. Roach III, US - M.R. Smith, US |
| 11:50am | DEBATE 3: "CLINICAL TRIALS DESIGN" Predictive models are a better way to stratify patients for clinical trials J.A. Eastham, US Standard stratification is adequate for clinical trials G.L. Andriole, US |
12:20am | PANEL DISCUSSION |
12:50am | Closing Remarks |
| * Discussion will follow each lecture | |